Aptar Group, a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Unidose Liquid System (Unidose) is the delivery system approved with neffy® (epinephrine nasal spray), the first and only needle-free treatment approved by the U.S. FDA for the emergency treatment of patients with allergic reactions (Type I), including anaphylaxis. This marks the first regulatory approval worldwide for nasally-delivered epinephrine.
Aptar Reports Second Quarter 2024 Results
Aptar Increases Quarterly Dividend by Nearly 10% Due to Continued Strong Performance
Aptar Releases 2023 Corporate Sustainability / ESG Report
Aptar Digital Health and Iona Mind Announce Partnership to Deliver Scalable Mental Health Support to Chronic Disease Patients
Aptar Receives Platinum Rating from EcoVadis for the Fourth Consecutive Year
Aptar Closures, an industry leader in dispensing solutions for over 50 years, has introduced a new intuitive, ultra-protective disc top closure. Designed with e-commerce applications in mind, the patent-pending, single-component E-Disc Top is the second in a series of three novel disc top dispensing solutions the company will introduce globally this year for beauty, personal care and home care products.
Aptar Reports First Quarter 2024 Results
Aptar Declares Quarterly Dividend
Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that the recent approval by the National Medical Products Administration (NMPA) in China of Sinomune Pharmaceutical’s Li Fu metronidazole gel for the treatment of papulopustular rosacea uses Aptar Pharma’s Mezzo+ CS (China Support) Airless dispensing solution for dermal drug delivery.